Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'No Second China': EU Firms Face Coronavirus Fallout

Executive Summary

The general economic and business impact on European firms from the coronavirus in China is widespread and severe, and companies must consider diversifying, warns an influential European trade group in a just-released business survey. But it concedes there are no China alternatives.

You may also be interested in...



Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On

More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.

Tighter Controls, Flood Of Orders Force Chinese Medical Suppliers To Say 'No' To The World

As global buyers rush to order protective face masks, testing kits and ventilators from China, the world's largest medical supplies producer, some manufacturers are refusing to take the orders.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC141746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel